Ascendis Pharma A/S
ASND
252.73
-3.23
-1.26%
Ascendis Pharma A/S
US · ASND
#1127 by market cap
Listed 2015
252.73
-3.23
-1.26%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Morgan Stanley Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $273Market Newswire · 2026/10/19
-
Rating change
CCORF Initiates Ascendis Pharma A/S(ASND.US) With Hold Rating, Announces Target Price $268Market Newswire · 2026/10/26
-
Rating change
H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $335Market Newswire · 2026/11/13
-
Rating change
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273Market Newswire · 2026/11/3
-
Ascendis Pharma A/S(ASND.US) Officer Sells US$5.28 Million in Common StockMarket Newswire · 2026/11/19
-
Rating change
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Argenx Se (ARGX) and Hinge Health, Inc. Class A (HNGE)TipRanks · 2026/10/12
-
Rating change
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Fractyl Health, Inc. (GUTS) and Ascendis Pharma (ASND)TipRanks · 2026/10/19
-
Form 144 | Ascendis Pharma A/S(ASND.US) Officer Proposes to Sell 5.28 Million in Common StocksMarket Newswire · 2026/11/18
-
Rating change
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $273Market Newswire · 2026/11/9
-
Citi Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $335Market Newswire · 2026/11/16
-
Rating change
UBS Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $269Market Newswire · 2026/10/16
-
Rating change
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy RatingMarket Newswire · 2026/10/9
-
Rating change
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $341Market Newswire · 2026/11/11
-
Rating change
Citi Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $330Market Newswire · 2026/10/26
-
Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $341Market Newswire · 2026/11/16
-
Rating change
UBS Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $269Market Newswire · 2026/10/15
-
Rating change
H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $344Market Newswire · 2026/11/9
-
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $274 to $356Market Newswire · 2026/11/14
-
Rating change
RBC Capital Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $290Market Newswire · 2026/10/9
-
Rating change
Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $329Market Newswire · 2026/9/30
-
Rating change
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $273 to $344Market Newswire · 2026/9/2
-
Rating change
Raymond James Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $287Market Newswire · 2026/9/15
-
Rating change
H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $344Market Newswire · 2026/8/31
-
Rating change
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275Market Newswire · 2026/8/31
-
Rating change
Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312Market Newswire · 2026/9/3
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Ascendis Pharma A/S discussion 0 comments